Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR) signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically expressed LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of LMP2B in EBV-harbouring Burkitt's lymphoma Akata cells results in reduced expression of EBV immediate-early lytic BZLF1 gene mRNA and late lytic gp350/220 protein upon BCR cross-linking. Similarly, reduction of lytic EBV activation was observed in Akata cells overexpressing LMP2A. In contrast, silencing of LMP2A expression resulted in higher lytic EBV mRNA and protein expression in BCR cross-linked Akata cells. These observations indicate a role for LMP2B distinct from that of LMP2A in regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B exhibits a negative-regulatory effect on the ability of LMP2A to maintain EBV latency by preventing the switch to lytic replication.
BabcockG. J.,
Thorley-LawsonD. A.2000; Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A 97:12250–12255[CrossRef]
BabcockG. J.,
HochbergD.,
Thorley-LawsonA. D.2000; The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497–506[CrossRef]
BernasconiM.,
BergerC.,
SigristJ. A.,
BonanomiA.,
SobekJ.,
NiggliF. K.,
NadalD.2006; Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray. Virol J 3:43[CrossRef]
DaibataM.,
HumphreysR. E.,
TakadaK.,
SairenjiT.1990; Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J Immunol 144:4788–4793
FruehlingS.,
LongneckerR.1997; The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241–251[CrossRef]
FruehlingS.,
LeeS. K.,
HerroldR.,
FrechB.,
LauxG.,
KremmerE.,
GrasserF. A.,
LongneckerR.1996; Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70:6216–6226
GrahamF. L.,
SmileyJ.,
RussellW. C.,
NairnR.1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74[CrossRef]
KonishiK.,
MaruoS.,
KatoH.,
TakadaK.2001; Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol 82:1451–1456
LongneckerR.,
DrukerB.,
RobertsT. M.,
KieffE.1991; An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65:3681–3692
LongneckerR.,
MillerC. L.,
MiaoX. Q.,
MarchiniA.,
KieffE.1992; The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol 66:6461–6469
LynchD. T.,
ZimmermanJ. S.,
RoweD. T.2002; Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells. J Gen Virol 83:1025–1035
MancaoC.,
AltmannM.,
JungnickelB.,
HammerschmidtW.2005; Rescue of ‘crippled’ germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106:4339–4344[CrossRef]
MatskovaL.,
ErnbergI.,
PawsonT.,
WinbergG.2001; C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol 75:10941–10949[CrossRef]
MerchantM.,
CaldwellR. G.,
LongneckerR.2000; The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 74:9115–9124[CrossRef]
MillerC. L.,
LeeJ. H.,
KieffE.,
LongneckerR.1994b; An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91:772–776[CrossRef]
PortisT.,
CooperL.,
DennisP.,
LongneckerR.2002; The LMP2A signalosome – a therapeutic target for Epstein-Barr virus latency and associated disease. Front Biosci 7:d414–d426[CrossRef]
RickinsonA. B.,
KieffE.2001; Epstein-Barr Virus. In Fields Virology , 4th edn. pp 2575–2627 Edited by
KnipeD. M.,
HowleyP. M.
Philadelphia, PA: Lippincott Williams & Wilkins;
SchaeferB. C.,
MitchellT. C.,
KapplerJ. W.,
MarrackP.2001; A novel family of retroviral vectors for the rapid production of complex stable cell lines. Anal Biochem 297:86–93[CrossRef]
SpeckP.,
KlineK. A.,
ChereshP.,
LongneckerR.1999; Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. J Gen Virol 80:2193–2203
StewartS.,
DawsonC. W.,
TakadaK.,
CurnowJ.,
MoodyC. A.,
SixbeyJ. W.,
YoungL. S.2004; Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A 101:15730–15735[CrossRef]
SwartR.,
RufI. K.,
SampleJ.,
LongneckerR.2000; Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J Virol 74:10838–10845[CrossRef]
VenturaA.,
MeissnerA.,
DillonC. P.,
McManusM.,
SharpP. A.,
Van ParijsL.,
JaenischR.,
JacksT.2004; Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 101:10380–10385[CrossRef]